Does Medicare Cover Alzheimer's Care?

For most of Medicare’s history, the answer to “Does Medicare cover Alzheimer’s care?” had a frustrating shape: yes for the doctor visits and the pills, no for everything that actually made the disease so expensive and exhausting to manage. The pills didn’t change the trajectory of the disease, and the care that consumed families financially — the supervision, the safety, the round-the-clock attention — wasn’t covered at all.

Two things have shifted that picture in the last two years, and both are worth understanding if someone in your family has Alzheimer’s. First, for the first time, Medicare covers drugs that actually slow early Alzheimer’s, not just mask its symptoms. Second, a new Medicare program pays for the care coordination and caregiver support that families used to piece together alone.

What hasn’t changed is the big one: the long-term custodial care that Alzheimer’s eventually demands is still on you. This page walks through all three.

The new drugs Medicare now covers

This is the genuinely new part, and it’s specific to Alzheimer’s (not dementia generally).

Leqembi (lecanemab) and Kisunla (donanemab) are monoclonal antibody infusions that clear amyloid plaques from the brain. In clinical trials they slowed cognitive decline in early Alzheimer’s by roughly 25–35% over 18 months. They are not cures, and they’re only for early-stage disease — but they’re the first treatments that change the course of the illness rather than just its symptoms.

Medicare covers both under Part B (they’re infused in a clinic, so they fall under the medical benefit, not the Part D drug benefit). Coverage requires:

• A confirmed diagnosis of early-stage Alzheimer’s — mild cognitive impairment or mild dementia due to Alzheimer’s
• Documented amyloid pathology (a PET scan or cerebrospinal fluid test)
• Treatment by a participating clinician who enrolls the patient in a CMS data-collection registry

The economics matter. Leqembi lists at about $26,500 per year. Under Part B, you owe 20% coinsurance — but if you have a Medigap policy, the supplement covers that 20%, so your out-of-pocket lands at essentially zero. Pre-treatment imaging and the periodic MRI scans needed to monitor for ARIA (a known side effect involving brain swelling or micro-bleeds) are also covered.

Whether these drugs are right for a given patient is a real clinical conversation — they carry meaningful risks and a significant infusion and monitoring burden, and they only help in the early window. But from a coverage standpoint, Medicare has opened the door, and Medigap makes the cost manageable.

The medications that have been around

The older Alzheimer’s drugs remain the foundation of symptomatic treatment, and they’re covered cheaply:

• Donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne) — cholinesterase inhibitors for mild-to-moderate Alzheimer’s
• Memantine (Namenda) — an NMDA receptor antagonist for moderate-to-severe Alzheimer’s
• Combination products like Namzaric

All are covered under Part D, almost always on Tier 1 or Tier 2, with copays in the $0–$15 range. These drugs manage symptoms and can modestly improve day-to-day function, but they don’t slow the underlying disease. For many families they remain a sensible, low-cost part of the treatment plan alongside or instead of the newer infusions.

Diagnosis is covered — and matters more now

Getting an accurate, documented Alzheimer’s diagnosis used to be mostly about planning. Now it’s also the key that unlocks the new drugs and the GUIDE program, so it’s worth doing properly.

Medicare Part B covers the full diagnostic pathway:

• The cognitive assessment built into the annual wellness visit (no cost)
• Neurological evaluation and specialist visits (20% coinsurance)
• Brain MRI to rule out other causes
• Amyloid PET scans where indicated — important because amyloid confirmation is required for Leqembi and Kisunla coverage
• Plasma biomarker blood tests as they enter clinical practice

Because amyloid confirmation gates the new drugs, an early, well-documented diagnosis is now more valuable than it used to be.

Care coordination: the GUIDE program

The Guiding an Improved Dementia Experience (GUIDE) program, which launched in July 2024, applies to Alzheimer’s and other dementias. Participating medical practices receive monthly Medicare payments to provide:

• A dedicated care navigator
• 24/7 access to a dementia-care phone line
• Caregiver education and training
• Up to $2,500/year of respite care, with no cost-sharing

For Alzheimer’s families specifically — who often face years of progressive caregiving — the navigator and respite components are genuinely valuable. Ask the treating neurologist or primary care office whether they participate. If your relative is in a Medicare Advantage plan rather than traditional Medicare, ask the plan what dementia care management it provides.

What Medicare won’t pay for

The hard limit is the same one that applies to all dementia: custodial care is not covered. That means Medicare does not pay for:

• A home aide to supervise, bathe, or dress your relative
• The monthly fee at a memory care or assisted living facility (typically $7,000–$9,000/month for memory care)
• Long-term nursing home placement for Alzheimer’s supervision
• Around-the-clock in-home supervision

Alzheimer’s is a long disease — the average duration from diagnosis is eight to ten years, sometimes longer — and the custodial-care costs over that span are the single largest financial burden families face. Medicare covers the doctors and the drugs; it does not cover the years of daily care.

Paying for the care Medicare won’t cover

The realistic funding sources, roughly in the order families use them:

1. Personal income and savings, until liquid assets run low
2. Long-term care insurance, if it was bought before diagnosis (cognitive impairment is a standard claim trigger)
3. VA Aid and Attendance for eligible wartime veterans and surviving spouses
4. Medicaid Home and Community-Based Services waivers once assets reach the eligibility threshold — state-specific, often with waiting lists
5. Hospice in the final stage, which covers the full medical and supportive layer

Because Alzheimer’s progresses over many years, the planning window is usually longer than for other terminal illnesses — use it. An elder law attorney can map a Medicaid-eligibility timeline before assets are exhausted, which often preserves more for a surviving spouse.

The honest summary

Medicare’s Alzheimer’s coverage in 2026 is the best it has ever been on the medical side: diagnosis, symptomatic drugs, the new disease-modifying infusions, and a real care-coordination program with built-in respite. On the custodial side — the supervision and daily care that define the lived experience of Alzheimer’s — Medicare covers essentially nothing, and that gap runs into the hundreds of thousands of dollars over the course of the disease.

Plan for both halves separately. Lean fully into the medical benefits Medicare now offers (especially GUIDE and, where appropriate, the new drugs), and build a separate, realistic plan for the years of custodial care that Medicare will never pay for. Our pages on dementia care, memory care, in-home care, and respite care go deeper on the funding side.